Stem Cells + Monoclonal Antibodies for Alzheimer's Disease

This trial tests whether combining stem cells with standard monoclonal antibody treatments can slow memory and function loss in individuals with mild Alzheimer's Disease. Participants will receive a stem cell infusion alongside their regular Alzheimer's medication. The trial seeks individuals diagnosed with mild Alzheimer's symptoms who are already on approved treatments like Leqembi or Donanemab. Participants should also have a friend or family member to assist in answering questions about daily activities. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you have been on an FDA-approved monoclonal antibody treatment for at least 6 months before joining. The protocol does not specify if you need to stop other medications, so it's best to discuss this with the trial team.

Research has shown that mesenchymal stem cells (MSCs) are generally safe for people with Alzheimer's disease. A review of 17 clinical trials found that Alzheimer's patients mostly tolerate MSC therapy well, with no major safety concerns. Another study found that MSCs are safe and may help treat brain disorders.

Unlike the standard treatments for Alzheimer's, which primarily focus on managing symptoms with medications like cholinesterase inhibitors and NMDA receptor antagonists, the investigational treatment involving monoclonal antibodies and mesenchymal stem cells offers a novel approach. This treatment is unique because it combines two cutting-edge therapies: monoclonal antibodies, which may target and neutralize harmful proteins in the brain, and mesenchymal stem cells, which have the potential to repair and regenerate damaged brain tissue. Researchers are excited about the possibility that this dual approach could not only slow the progression of Alzheimer's but also potentially restore cognitive function, offering new hope for patients and their families.

Research has shown that certain stem cells, called mesenchymal stem cells (MSCs), might help treat Alzheimer's Disease (AD). Clinical trials have found that MSC therapy is generally safe and can improve symptoms in people with AD. Animal studies suggest that MSCs can ease Alzheimer's symptoms, boost memory and thinking skills, and reduce harmful brain plaque. One study found that patients receiving MSC treatment showed better results in clinical tests compared to those who received a placebo. Additionally, MSCs might help lower brain inflammation, which plays a significant role in Alzheimer's progression. Overall, early research suggests that MSCs could be a promising way to slow down memory and thinking decline in Alzheimer's patients. Participants in this trial will receive an infusion of human mesenchymal stem cells to further evaluate these potential benefits.¹²⁴⁵⁶